These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31613319)

  • 1. Noninvasive Evaluation of GPR119 Agonist Effects on β-Cell Mass in Diabetic Male Mice Using 111In-Exendin-4 SPECT/CT.
    Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Matsumoto K; Inagaki N
    Endocrinology; 2019 Dec; 160(12):2959-2968. PubMed ID: 31613319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using
    Fauzi M; Murakami T; Fujimoto H; Botagarova A; Sakaki K; Kiyobayashi S; Ogura M; Inagaki N
    Front Endocrinol (Lausanne); 2022; 13():1010825. PubMed ID: 36246910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with
    Hamamatsu K; Fujimoto H; Fujita N; Murakami T; Shiotani M; Toyoda K; Inagaki N
    Sci Rep; 2019 Dec; 9(1):18338. PubMed ID: 31797889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive quantitative evaluation of viable islet grafts using
    Botagarova A; Murakami T; Fujimoto H; Fauzi M; Kiyobayashi S; Otani D; Fujimoto N; Inagaki N
    FASEB J; 2023 Apr; 37(4):e22859. PubMed ID: 36906290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of an
    Kimura H; Fujita N; Kanbe K; Matsuda H; Watanabe H; Arimitsu K; Fujimoto H; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
    Bioorg Med Chem; 2017 Oct; 25(20):5772-5778. PubMed ID: 28927802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet.
    Kiyobayashi S; Murakami T; Harada N; Fujimoto H; Murata Y; Fujita N; Hamamatsu K; Ikeguchi-Ogura E; Hatoko T; Lu X; Yamane S; Inagaki N
    Front Endocrinol (Lausanne); 2022; 13():921125. PubMed ID: 35909510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive longitudinal quantification of β-cell mass with [
    Fujita N; Fujimoto H; Hamamatsu K; Murakami T; Kimura H; Toyoda K; Saji H; Inagaki N
    FASEB J; 2019 Nov; 33(11):11836-11844. PubMed ID: 31370679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.
    Murakami T; Fujimoto H; Inagaki N
    Front Endocrinol (Lausanne); 2021; 12():714348. PubMed ID: 34248856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the Pancreatic β Cell Mass in Vivo with Exendin SPECT during Hyperglycemia and Severe Insulitis.
    Joosten L; Brom M; Peeters H; Bos D; Himpe E; Bouwens L; Boerman O; Gotthardt M
    Mol Pharm; 2019 Sep; 16(9):4024-4030. PubMed ID: 31345042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study.
    Terauchi Y; Yamada Y; Watada H; Nakatsuka Y; Shiosakai K; Washio T; Taguchi T
    J Diabetes Investig; 2018 Nov; 9(6):1333-1341. PubMed ID: 29607623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.
    Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N
    J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
    Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.
    Brom M; Woliner-van der Weg W; Joosten L; Frielink C; Bouckenooghe T; Rijken P; Andralojc K; Göke BJ; de Jong M; Eizirik DL; Béhé M; Lahoutte T; Oyen WJ; Tack CJ; Janssen M; Boerman OC; Gotthardt M
    Diabetologia; 2014 May; 57(5):950-9. PubMed ID: 24488022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
    Zhang M; Feng Y; Wang J; Zhao J; Li T; He M; Yang D; Nosjean O; Boutin J; Renard P; Wang MW
    PLoS One; 2013; 8(5):e63861. PubMed ID: 23704946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a method for in-vivo SPECT/CT imaging analysis of
    Hamamatsu K; Fujimoto H; Fujita N; Murakami T; Kimura H; Saji H; Inagaki N
    Nucl Med Biol; 2018; 64-65():22-27. PubMed ID: 30015092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.
    Kim MK; Cheong YH; Lee SH; Kim TH; Jung IH; Chae Y; Lee JH; Yang EK; Park H; Yang JS; Hong KW
    Biomed Pharmacother; 2021 Dec; 144():112324. PubMed ID: 34678732
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.